Jesper Fleischer

Effect of 12-week continuous positive airway pressure therapy on glucose levels assessed by continuous glucose monitoring in people with type 2 diabetes and obstructive sleep apnoea; a randomized controlled trial

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Anne Margareta Banghøj, Københavns Universitet
  • ,
  • Christoffer Krogager
  • Peter Lommer Kristensen, Department of Endocrinology and Nephrology, Københavns Universitet
  • ,
  • Klavs Würgler Hansen, Diagnostic Centre, Aarhus Universitet
  • ,
  • Esben Laugesen
  • Jesper Fleischer
  • Simon Lebech Cichosz, Department of Health Science and Technology, Aalborg Universitet
  • ,
  • Per Løgstrup Poulsen
  • Martin Glymer Kirkegaard, Aarhus Universitet
  • ,
  • Birger Thorsteinsson, Københavns Universitet
  • ,
  • Lise Tarnow, Novo Nordisk A/S, Københavns Universitet

Aim: Obstructive sleep apnoea (OSA) is frequent in type 2 diabetes (T2D). The aim was to investigate the effect of a 12-week treatment with continuous positive airway pressure (CPAP) on glycaemic control assessed by continuous glucose monitoring (CGM), HbA1c and fasting blood glucose in patients with T2D and newly detected OSA. Methods: In a randomized controlled multicentre study, 72 participants with T2D and moderate to severe OSA (78% male, age 62 ± 7, AHI 35 ± 15) were recruited from outpatient clinics in three Danish hospitals and were randomized to CPAP intervention or control. The main outcome was glycaemic control assessed by 6 days CGM at baseline and after 12-week therapy, as well as by HbA1c and fasting blood glucose. Results: No significant changes were found in average glucose levels, time in glucose range, time with hypoglycaemia, time with hyperglycaemia or coefficient of variability. HbA1c decreased 0.7 mmol/mol (0.07%; P =.8) in the CPAP group and increased 0.8 mmol/mol (0.08%; P =.6) in the control group (intergroup difference, P =.6). Fasting blood glucose increased by 0.2 mmol/L (P =.02) in the CPAP group and by 0.4 mmol/L (P =.01) in the control group (intergroup difference, P =.7). In a prespecified subgroup analysis comparing participants with high adherence (minimum usage of four hours/night for 70% of all nights) to CPAP to the control group, no significant changes were observed either, although these participants had a tendency towards better glycaemic indices. Conclusions: CPAP treatment for 12 weeks does not significantly change glycaemic control in patients with type 2 diabetes and OSA.

OriginalsprogEngelsk
TidsskriftEndocrinology, Diabetes and Metabolism
ISSN2398-9238
DOI
StatusAccepteret/In press - 1 jan. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 196720631